Luca G.
- Country
- Italy
- Department
- S.C. Ematologia
Research Overview
- Efficacy, Safety, and Tolerability of Itepekimab in Non-Cystic Fibrosis Bronchiectasis: A Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Amikacin Liposome Inhalation Suspension with Azithromycin and Ethambutol in Adult Patients with MAC-Induced NTM Lung Infection
Data & Insights
Has run more than one trial at 17 of 93 partner sites.
Specializations
Respiratory Infections
This investigator specializes in treating nontuberculous mycobacterial lung infections, particularly those caused by Mycobacterium avium Complex (MAC). Their research encompasses innovative therapeutic approaches for newly diagnosed cases.
- MAC lung infections
- Liposomal therapeutic delivery systems
- Antimycobacterial treatment strategies
The investigator focuses on evaluating novel treatment combinations incorporating advanced drug delivery methods for respiratory infections.
Bronchial Disorders
The investigator has significant expertise in treating non-cystic fibrosis bronchiectasis (NCFB), exploring innovative biological therapies targeting specific inflammatory pathways.
- Bronchiectasis management
- Pulmonary exacerbations
- Immunological therapies
Their work involves assessing novel therapeutic approaches for bronchiectasis, particularly focusing on immunomodulatory treatments.
Inflammatory Respiratory Disease
The investigator specializes in treating chronic respiratory conditions with a focus on inflammatory pathway modulation. Their expertise extends to evaluating targeted biological therapies.
- Anti-inflammatory treatments
- Monoclonal antibody therapies
- Respiratory disease management
Their research explores the intersection of inflammatory mechanisms and respiratory disease progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.